Nuvectis Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nuvectis Pharma Inc (NVCT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nuvectis Pharma Inc vs Its Competitors
- Scale: Nuvectis Pharma Inc ranks #196 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Nuvectis Pharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nuvectis Pharma inc | - | - | - | Yes |
| Competitors combined (58) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NVCT Stock Performance relative to its Competitors
NVCT Stock Performance relative to High-Confidence Competitors
NVCT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 4 | Evoke Pharma Inc | 282.9% | Outperformed |
| 5 | Enliven Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nuvectis Pharma Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Nuvectis Pharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Nuvectis Pharma inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Nuvectis Pharma inc | 467.41 | - |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Madrigal Pharmaceuticals Inc | 14,772.03 | 1,283.94 |
| Hutchmed china Limited | 12,316.49 | 548.51 |
| Nuvalent Inc | 9,751.98 | 4.23 |
| Merus N v | 6,810.81 | 56.61 |
| SUBTOTAL | 211,100.20 | 53,600.70 |
Sign in to see all competitors of Nuvectis Pharma inc .
Sources: Nuvectis Pharma inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nuvectis Pharma inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nuvectis Pharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AstraZeneca | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Nuvectis Pharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Nuvectis Pharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nuvectis Pharma inc | 467 | - | -2,328,846 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Madrigal Pharmaceuticals Inc | 14,772 | 1,403,213 | -355,295 |
| Hutchmed china Limited | 12,316 | 703,221 | 586,836 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| PEERS TOTAL | 210,633 | 1,353,314 | 160,775 |
Sign in to see all peers for Nuvectis Pharma inc .
Nuvectis Pharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 67.79 % |
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Nuvectis Pharma Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Nuvectis Pharma inc .
Nuvectis Pharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Nuvectis Pharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Nuvectis Pharma Inc ranks #196 of 498 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 196 | Nuvectis Pharma inc | 467 | 0.01 % |
Market cap and industry share for the rest of Nuvectis Pharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Nuvectis Pharma Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 191 | Kamada Ltd | 501 | 28.48 % |
| 192 | Sagimet Biosciences inc | 493 | 29.97 % |
| 193 | Arvinas Inc | 487 | -4.26 % |
| 194 | Oculis Holding Ag | 482 | -47.31 % |
| 195 | Capricor Therapeutics inc | 1,234 | 12.3% |
| 196 | Nuvectis Pharma inc | 467 | 234.62 % |
| 197 | Maplight Therapeutics Inc | 1,234 | 12.3% |
| 198 | Contineum Therapeutics Inc | 1,234 | 12.3% |
| 199 | Benitec Biopharma Inc | 1,234 | 12.3% |
| 200 | Assembly Biosciences Inc | 1,234 | 12.3% |
| 201 | Vtv Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Nuvectis Pharma Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Nuvectis Pharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 21.5x | 4.5x | +17.0x |
| Return on Equity | -184.25 % | industry aggregate | -201.50 % |
| Return on Invested Capital | -87.84 % | -2.95 % (avg) | -84.89 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nuvectis Pharma Inc's BCG Growth-Share Matrix
Relative market share (vs Nuvectis Pharma Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) — a common framework, not a precision instrument.
Nuvectis Pharma Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Nuvectis Pharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Nuvectis Pharma Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Nuvectis Pharma Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Nuvectis Pharma Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Nuvectis Pharma Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Nuvectis Pharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 201.5 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (49.10 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Nuvectis Pharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nuvectis Pharma inc | 2.32 | 2.33 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Merus N v | 3.67 | 7.20 | - |
Sign in to see all peers for Nuvectis Pharma inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nuvectis Pharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nuvectis Pharma inc | Q2 2026 | - | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| PEERS TOTAL | +6.7 % | +1,417.9 % |
Sign in to see all peers for Nuvectis Pharma inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nuvectis Pharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nuvectis Pharma inc | Q2 2026 | - | - |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Merus N v | Q3 2025 | - | +21.0 % |
Sign in to see all peers for Nuvectis Pharma inc .
Nuvectis Pharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nuvectis Pharma inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
| Nuvalent Inc | - | - | - |
| Merus N v | - | - | - |
Sign in to see all peers for Nuvectis Pharma inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nuvectis Pharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nuvectis Pharma inc | - | - |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Madrigal Pharmaceuticals Inc | - | 11.51 |
| Hutchmed china Limited | 27.13 | 22.45 |
| Nuvalent Inc | - | 2,303.80 |
| Merus N v | - | 120.32 |
| PEERS AVERAGE | 33.31 | 3.94 |
Sign in to see all peers for Nuvectis Pharma inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.